Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

ACADIA Pharmaceuticals (0A4W) Share Price & Analysis

0 Followers

0A4W Stock Chart & Stats

$26.87$0.00(0.00%)
At close: 4:30 PM GMT
$15$20$25$30Sep 1Mar 2Sep 1Mar 1Sep 3Jan 30
Day’s Range
$26.87 - $26.87
52-Week Range
$18.62 - $26.87
Previous Close
$26.87
Volume
N/A
Average Volume (3M)
0
Market Cap
$3.16B
Enterprise Value
$2.63B
Total Cash (Recent Filing)
$976.45M
Total Debt (Recent Filing)
$71.85M
Price to Earnings (P/E)
8.6
Beta
0.11
Next Earnings
Mar 01, 2027 (Est.)
EPS Estimate
0.27
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Expansion

Raised 2026 guidance and stated 2028 sales ambitions for both medicines indicate management sees commercial expansion as durable, not dependent on a single quarter. DAYBUE and NUPLAZID growth can broaden the revenue base, support operating leverage, and fund continued CNS investment.

Balance Sheet Strength

Low leverage and expanding equity provide financial resilience while ACADIA invests in commercialization and clinical development. The shift to positive returns on equity also shows that improved capitalization is being supported by a meaningful profitability turnaround rather than balance-sheet growth alone.

Extended Product Protection

Protection through 2041 could preserve DAYBUE’s commercial economics for many years and give ACADIA a durable period to expand diagnosis, community-practice use, and international access. Longer exclusivity also supports confidence in funding pipeline development from an established product franchise.

Bears Say

Free Cash Flow Volatility

The sharp recent decline in free cash flow weakens confidence in the quality and repeatability of reported earnings. If cash conversion remains below net income, ACADIA may have less internally generated flexibility for clinical programs, commercial investment, and business development despite positive profitability.

Cooling Revenue Growth

Slower revenue growth and less consistent operating profitability suggest that the initial acceleration is moderating. This could make future earnings more dependent on execution, expense control, and successful indication expansion, reducing visibility into how sustainably current profit levels can compound.

Clinical Development Risk

The missed primary endpoint raises uncertainty around remlifanserin’s probability of success and the timing of any future contribution from the program. Although the 60-milligram dose showed supportive secondary results, additional development and regulatory work remain necessary before commercialization.

ACADIA Pharmaceuticals News

0A4W FAQ

What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest share price was $18.62 and its highest was $26.87 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $3.16B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s next earnings report is estimated for Mar 01, 2027 (not yet confirmed), which is in 108 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Nov 04, 2026. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.199 by $0.111.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.27.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 172,828,980 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.31 in its last earnings report, beating expectations of $0.199. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Hedge funds hold ACADIA Pharmaceuticals shares: the largest hedge-fund position in ACADIA Pharmaceuticals is 1,125,304,715 shares, and hedge funds decreased their holdings by 798.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology